Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Groups representing drug companies heavily increased their federal lobbying in President Trump's first year, according to a review of lobbying records. No health care lobbying group splurged more than the Pharmaceutical Research and Manufacturers of America, which spent $25.4 million in 2017 — a 30% jump from 2016.

The big picture: The pharmaceutical industry went on red alert after Trump said drug companies were "getting away with murder" and had "a lot of power." It's worked: In the year since, Trump and Congress have not changed drug pricing laws.

Expand chart
Data: U.S. Senate Lobbying Disclosure Act Database; Chart: Chris Canipe / Axios

The details: PhRMA spent the most in the first quarter, when Trump made his "getting away with murder" comments. The group lobbied on a plethora of issues, including fighting against measures that would allow importation of cheaper drugs and support of cutting drug subsidies to hospitals.

  • The Biotechnology Innovation Organization, another drug industry lobbying group, held its spending steady at $9.4 million in 2017.
  • The Association for Accessible Medicines, which represents generic drug makers, boosted its federal lobbying budget by 21% to $3.5 million.
  • The American Medical Association was the second-biggest spender on federal lobbying, raising its 2017 expenses by 11%, to $20.9 million.
  • The American Hospital Association spent $17.5 million last year, but that was actually a 7% decline.
  • The insurance industry also pulled back: Lobbying expenses dropped by 6% at America's Health Insurance Plans and 5% at the Blue Cross Blue Shield Association, even though Congress was pushing bills that would have cut Medicaid and individual health insurance subsidies.
  • Medical device lobbying group AdvaMed spent 14% more in Trump's first year and was rewarded with another two-year delay of the Affordable Care Act's medical device tax.

One big number: Overall, federal lobbying at just these 12 health care trade groups totaled $109 million in 2017 — or about $34 million more than what the Centers for Disease Control and Prevention spends on its opioid abuse and overdose prevention program. And that figure doesn't include the industry lobbying at the state level.

Go deeper

White House: Over 110 million COVID-19 vaccine doses shipped, donated

Photo: Photo by Anna Moneymaker/Getty Images

The U.S. has shipped and donated more than 110 million coronavirus vaccine doses to over 60 countries, the White House said Friday.

Why it matters: It is more than the combined donations of all other countries, the White House said, citing the United Nations. Biden had pledged to donate at least 80 million vaccines by the end of June.

Why companies aren't paying more

Illustration: Aïda Amer/Axios

If companies raised pay high enough, then maybe they wouldn’t complain about labor shortages that have forced them to forgo sales. But there seems to be a limit to how much a company is willing to pay, despite what seems like a clear opportunity to maximize the top line.

Why it matters: Companies have been scrambling to staff up amid a rapid economic recovery. Employers across industries have been raising wages in their efforts to be competitive.

Business travel might be going out of style

Illustration: Annelise Capossela/Axios

Companies have made it a year and a half mostly without traveling for work — and now more and more of them are considering dramatically reducing business travel to slash costs and cut carbon emissions.

Why it matters: Business travel is a massive part of the global economy — with trillions of dollars and millions of jobs at airlines, hotels and travel agencies hinging on its return.